Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Concerns rise over obesity care startups

Concerns emerge over a wave of new startups offering access to drugs called GLP-1 agonists

Salon

Weight loss drug causing chaos on TikTok

A diabetes drug is all the rage among Hollywood’s elite, but folks who need the drug are struggling to get it

Salon

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

‘I miss eating’: the truth behind the weight loss drug that makes food repulsive

In Beverly Hills’ doctors offices, celebrities are clamoring for Ozempic prescriptions – but what are the costs of the supposed wonder drug?

The Guardian - US

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Stocks No One Is Talking About but Should Be

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan Machinery (TITN) are currently not on investors’ radar, but it could be worth adding these stocks to one’s portfolio given…

StockNews.com

A new ‘miracle’ weight-loss drug really works — raising huge questions

Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

Financial Times

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Upgrades

Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

Benzinga

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - AU

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

Benzinga

Peering Into Novo Nordisk's Recent Short Interest

Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

Benzinga

If You Invested $100 In Novo Nordisk 10 Years Ago, Here's How Much You Would Have Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Novo Nordisk Shares Are Trading Higher Today

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

Benzinga

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

Benzinga

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Benzinga

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE: NVO)

Benzinga

Novo Nordisk: Q4 Earnings Insights

Novo Nordisk (NYSE:NVO) reported its Q4 earnings results on Wednesday, February 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement.

1 … 24 25 26 27

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.